| In the literature: August 2021 V Gambardella, C Alfaro-Cervelló, JM Cejalvo, M Tapia, A Cervantes ESMO open 6 (5), 2021 | | 2021 |
| Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer T Yoshino, G Argilés, E Oki, E Martinelli, H Taniguchi, D Arnold, ... Annals of Oncology, 2021 | | 2021 |
| Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges G Bruixola, E Remacha, A Jiménez-Pastor, D Dualde, A Viala, JV Montón, ... Cancer Treatment Reviews, 102263, 2021 | | 2021 |
| Beyond the lessons learned from the Covid19 pandemic: Opportunities to optimize clinical trial implementation in oncology L Castelo-Branco, A Awada, G Pentheroudakis, JL Perez-Garcia, J Mateo, ... ESMO open, 100237, 2021 | | 2021 |
| First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma A Italiano, PA Cassier, CC Lin, T Alanko, KJ Peltola, A Gazzah, HS Shiah, ... Cancer Immunology, Immunotherapy, 1-15, 2021 | | 2021 |
| LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer Z Wainberg, I Matos, J Delord, P Cassier, M Gil-Martin, T Kim, P LoRusso, ... Annals of Oncology 32, S227-S228, 2021 | | 2021 |
| O-7 FOLFIRI±napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study M Shah, T Yoshino, N Tebbutt, A Grothey, J Tabernero, R Xu, J Taieb, ... Annals of Oncology 32, S220, 2021 | | 2021 |
| Abstract LB061: On-target peripheral and tumor immune microenvironment modulation in patients treated with lacnotuzumab (anti-CSF1, MCS110)+ spartalizumab J Wu, S Chen, G Baneyx, AL Marchal, DS Quinn, M Martin, A Cervantes, ... Cancer Research 81 (13 Supplement), LB061-LB061, 2021 | | 2021 |
| Abstract CT192: Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from … M Ponz-Sarvisé, E Élez, A Muñoz, M Van den Eynde, AG Rampoldi, ... Cancer Research 81 (13 Supplement), CT192-CT192, 2021 | | 2021 |
| Abstract CT217: Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors K Harrington, E Parkes, J Weiss, M Ingham, A Cervantes, E Calvo, ... Cancer Research 81 (13 Supplement), CT217-CT217, 2021 | | 2021 |
| Peritoneal invasion and metachronous peritoneal metastases after colon cancer surgery: The role of homogeneous, reliable assessment and confounders. G Pellino, E García-Granero, A Cervantes European Journal of Surgical Oncology: the Journal of the European Society …, 2021 | | 2021 |
| Retrospective study of regorafenib versus TAS-102 efficacy and safety in chemorefractory metastatic colorectal cancer (mCRC) patients: a multi institution real life clinical data. P Vitale, N Zanaletti, V Famiglietti, V De Falco, A Cervantes, S Rosellò, ... Clinical Colorectal Cancer, 2021 | | 2021 |
| The COVID-19 pandemic could be a setback for gender equality in oncology—and a key moment to push ahead with transformative policies A Cervantes ESMO open, 2021 | | 2021 |
| GUT VASCULAR BARRIER IMPAIRMENT LEADS TO INTESTINAL BACTERIA DISSEMINATION AND COLORECTAL CANCER METASTASIS TO LIVER V Gambardella, L Candia, M Tapia, JM Cejalvo, A Cervantes ESMO OPEN 6 (3), 2021 | | 2021 |
| PATTERNS OF TRANSCRIPTION FACTOR PROGRAMS AND IMMUNE PATHWAY ACTIVATION IN SMALL-CELL LUNG CANCER P Martin-Martorell, I Gonzalez-Barrallo, V Gambardella, JM Cejalvo, ... ESMO OPEN 6 (3), 2021 | | 2021 |
| A phase I/Ib study evaluating GDC-0077 (inavolisib)+ palbociclib (palbo)+ fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative … P Schmid, PL Bedard, K Jhaveri, A Cervantes, V Gambardella, E Hamilton, ... Senologie-Zeitschrift für Mammadiagnostik und-therapie 18 (02), 85, 2021 | | 2021 |
| In the literature: June 2021 V Gambardella, L Candia, M Tapia, JM Cejalvo, A Cervantes ESMO open 6 (3), 2021 | | 2021 |
| Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines A Vogel, E Martinelli, ESMO Guidelines Committee Annals of oncology: official journal of the European Society for Medical …, 2021 | 9 | 2021 |
| Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation MT Martínez, J Montón-Bueno, S Simon, B Ortega, S Moragon, S Roselló, ... ESMO open 6 (3), 100148, 2021 | | 2021 |
| ESMO pays tribute to Professor José Baselga S Peters, J Tabernero, A Cervantes, S Banerjee, R Giuliani, F Lordick ESMO open 6 (3), 2021 | | 2021 |
Susana RosellóMedical Doctor in Hospital Clinico Universitario of Valencia, SpainDirección de correo verificada de incliva.es
